$TRML
Tourmaline Bio, Inc. Stock $trml

$trml Overview Financials Valuation SEC Filings Company Website

2021 Q1 Form 10-Q Financial Statement

#000156459021032784 Filed on June 14, 2021

Income Statement

Concept	2021 Q1	2020 Q1
Revenue	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.537M	$1.439M
YoY Change	76.3%
% of Gross Profit
Research & Development	$6.468M	$3.535M
YoY Change	82.97%
% of Gross Profit
Depreciation & Amortization	$135.0K	$92.00K
YoY Change	46.74%
% of Gross Profit
Operating Expenses	$9.005M	$4.974M
YoY Change	81.04%
Operating Profit	-$9.005M	-$4.974M
YoY Change	81.04%
Interest Expense	-$294.0K	$126.0K
YoY Change	-333.33%
% of Operating Profit
Other Income/Expense, Net	-$294.0K	$126.0K
YoY Change	-333.33%
Pretax Income	-$9.299M	-$4.848M
YoY Change	91.81%
Income Tax
% Of Pretax Income
Net Earnings	-$9.299M	-$4.848M
YoY Change	91.81%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$225.5K	-$117.6K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept	2021 Q1	2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$140.1M
YoY Change
Cash & Equivalents	$9.900M	$14.28M
Short-Term Investments	$130.2M
Other Short-Term Assets	$67.00K
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$142.8M
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment	$2.083M
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$14.00K
YoY Change
Total Long-Term Assets	$2.097M
YoY Change
TOTAL ASSETS
Total Short-Term Assets	$142.8M
Total Long-Term Assets	$2.097M
Total Assets	$144.9M
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$769.0K
YoY Change
Accrued Expenses	$2.812M
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$3.581M
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt	$0.00
YoY Change
Other Long-Term Liabilities	$1.634M
YoY Change
Total Long-Term Liabilities	$1.634M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.581M
Total Long-Term Liabilities	$1.634M
Total Liabilities	$5.215M
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings	-$52.30M
YoY Change
Common Stock	$5.838M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$46.47M	-$21.81M
YoY Change
Total Liabilities & Shareholders Equity	$144.9M
YoY Change

Cashflow Statement

Concept	2021 Q1	2020 Q1
OPERATING ACTIVITIES
Net Income	-$9.299M	-$4.848M
YoY Change	91.81%
Depreciation, Depletion And Amortization	$135.0K	$92.00K
YoY Change	46.74%
Cash From Operating Activities	-$9.047M	-$5.243M
YoY Change	72.55%
INVESTING ACTIVITIES
Capital Expenditures	$187.0K	$349.0K
YoY Change	-46.42%
Acquisitions
YoY Change
Other Investing Activities	$1.517M	-$19.11M
YoY Change	-107.94%
Cash From Investing Activities	$1.330M	-$19.46M
YoY Change	-106.84%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	17.00K
YoY Change
NET CHANGE
Cash From Operating Activities	-9.047M	-5.243M
Cash From Investing Activities	1.330M	-19.46M
Cash From Financing Activities	17.00K
Net Change In Cash	-7.700M	-24.70M
YoY Change	-68.82%
FREE CASH FLOW
Cash From Operating Activities	-$9.047M	-$5.243M
Capital Expenditures	$187.0K	$349.0K
Free Cash Flow	-$9.234M	-$5.592M
YoY Change	65.13%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2021Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2021Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001827506
CY2021Q1	us-gaap	Lessee Operating Lease Existence Of Option To Extend LesseeOperatingLeaseExistenceOfOptionToExtend	true
CY2021Q1	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2023-11-30
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y4M24D
CY2021Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y2M23D
CY2021Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P8Y4M17D
CY2021Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y11M26D
CY2021Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2021Q1	dei	Entity Shell Company EntityShellCompany	false
CY2020Q4	tals	Contingent Stock Liability ContingentStockLiability	373000
CY2020Q4	us-gaap	Liabilities Liabilities	4774000
CY2021Q1	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	186151000
CY2020Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	186151000
CY2021Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	36366101
CY2021Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	7204311
CY2021Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	7204311
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	36366101
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	7087130
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	7087130
CY2021Q1	us-gaap	Common Stock Value CommonStockValue	1000
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	1000
CY2021Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	5837000
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	4879000
CY2021Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-52313000
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-43014000
CY2021Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	9000
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-13000
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	-46466000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-38147000
CY2021Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	144900000
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	152778000
CY2021Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6468000
CY2020Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3535000
CY2020Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1439000
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-9005000
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-4974000
CY2021Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-294000
CY2020Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	126000
CY2021Q1	us-gaap	Profit Loss ProfitLoss	-9299000
CY2021Q1	dei	Amendment Flag AmendmentFlag	false
CY2021Q1	dei	Document Type DocumentType	10-Q
CY2021Q1	dei	Document Period End Date DocumentPeriodEndDate	2021-03-31
CY2021Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2021Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	83-2377352
CY2021Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021Q1	dei	Entity Registrant Name EntityRegistrantName	TALARIS THERAPEUTICS, INC.
CY2021Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2021Q1	dei	Entity File Number EntityFileNumber	001-40384
CY2021Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	570 S. Preston St
CY2021Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021Q1	dei	Trading Symbol TradingSymbol	TALS
CY2021Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2020Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	131899000
CY2021Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	No
CY2021Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2021Q1	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2020Q4	us-gaap	Assets Current AssetsCurrent	150751000
CY2021Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2020Q4	tals	Share Repurchase Liability ShareRepurchaseLiability	996000
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1263000
CY2021Q1	us-gaap	Assets Current AssetsCurrent	142803000
CY2021Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	14000
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	14000
CY2021Q1	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	130212000
CY2021Q1	us-gaap	Assets Assets	144900000
CY2021Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2702000
CY2021Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	769000
CY2021Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2083000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2013000
CY2020Q4	us-gaap	Assets Assets	152778000
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	767000
CY2021Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2812000
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2637000
CY2021Q1	us-gaap	Liabilities Current LiabilitiesCurrent	3581000
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3404000
CY2021Q1	tals	Share Repurchase Liability ShareRepurchaseLiability	901000
CY2021Q1	tals	Contingent Stock Liability ContingentStockLiability	733000
CY2021Q1	us-gaap	Liabilities Liabilities	5215000
CY2020Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	13000
CY2020Q1	us-gaap	Operating Expenses OperatingExpenses	4974000
CY2021Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-9277000
CY2021Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	41310241
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9889000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	17589000
CY2021Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2537000
CY2021Q1	us-gaap	Operating Expenses OperatingExpenses	9005000
CY2020Q1	us-gaap	Profit Loss ProfitLoss	-4848000
CY2021Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	22000
CY2020Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-4835000
CY2021Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-9277000
CY2020Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4835000
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-9299000
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-4848000
CY2021Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.30
CY2020Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.76
CY2021Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	7160631
CY2020Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	6390771
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	-17102000
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	123000
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-4848000
CY2020Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	13000
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	-21814000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-38147000
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	123000
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	835000
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-9299000
CY2021Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	22000
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	-46466000
CY2021Q1	us-gaap	Profit Loss ProfitLoss	-9299000
CY2020Q1	us-gaap	Profit Loss ProfitLoss	-4848000
CY2021Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	135000
CY2020Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	92000
CY2021Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-193000
CY2020Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	49000
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	835000
CY2020Q1	us-gaap	Share Based Compensation ShareBasedCompensation	123000
CY2021Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	360000
CY2021Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	400000
CY2020Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	4000
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1000
CY2020Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	138000
CY2021Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-872000
CY2020Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-695000
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9047000
CY2020Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5243000
CY2021Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	187000
CY2020Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	349000
CY2021Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	34297000
CY2020Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	19106000
CY2021Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	35814000
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	1330000
CY2020Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-19455000
CY2021Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	11000
CY2021Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	28000
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	17000
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-7700000
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-24698000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	17589000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	38978000
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	9889000
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	14280000
CY2021Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	106000
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-19200000
CY2021Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-52300000
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9900000
CY2021Q1	us-gaap	Marketable Securities MarketableSecurities	130200000
CY2020Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	35000
CY2021Q1	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	1039000
CY2020Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	131912000
CY2021Q1	us-gaap	Nature Of Operations NatureOfOperations	<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1. Nature of Business and Liquidity </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Talaris Therapeutics, Inc. (“Talaris” or the “Company”) is a late-clinical stage, cell therapy company developing an innovative method of allogeneic hematopoietic stem cell transplantation (“allo-HSCT”), called Facilitated Allo-HSCT Therapy, that the Company believes has the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases and certain severe non-malignant blood, immune and metabolic disorders. The Company believes that these indications, individually and collectively, represent a significant unmet need and commercial opportunity. The Company maintains corporate offices in Boston, Massachusetts and its cell processing facility in Louisville, Kentucky.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:3.4%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> <span style="font-weight:bold;font-style:italic;">Initial Public Offering </span></p> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As described in Note 13, the Company completed an initial public offering in May 2021. Upon completion of the offering, the Company’s outstanding convertible preferred stock was automatically converted into shares of common stock and non-voting common stock. Prior to the offering, the Company’s board of directors and shareholders approved a <span style="-sec-ix-hidden:F_000557"><span style="-sec-ix-hidden:F_000276_2">one-for-5.35</span></span> reverse share split of issued and outstanding common shares and incentive shares and a proportional adjustment to the existing conversion ratios for the Company’s convertible preferred stock.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:3.4%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Liquidity </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. Management has evaluated whether there are conditions and events that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date the financial statements are issued. Since its inception, the Company has incurred net losses and negative cash flows from operations. During the three months ended March 31, 2021 and the year ended December 31, 2020, the Company incurred a net loss of $9.3 million and $22.7 million, respectively, and used $9.0 million and $19.2 million in cash for operations, respectively. In addition, as of March 31, 2021, the Company had an accumulated deficit of $52.3 million. The Company expects to continue to generate operating losses and negative cash flows for the foreseeable future. The Company currently expects the cash and cash equivalents on hand of $9.9 million and marketable securities of $130.2 million as of March 31, 2021, together with the net proceeds from the Company’s initial public offering (“IPO”), after deducting underwriting discounts and commissions but before deducting offering costs, of approximately $139.5 million in May 2021, will be sufficient to fund its operating expenses and capital requirements for more than 12 months from the date the financial statements are available to be issued. </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional funding will be needed to finance future clinical, pre-clinical, manufacturing and commercial activities. There is no assurance the Company will be successful in obtaining such additional financing on terms acceptable to it, if at all, and it may not be able to enter into other arrangements. If the Company is unable to obtain funding, it could be forced to delay, reduce or eliminate our research and development programs, portfolio expansion or commercialization efforts, which could adversely affect its business prospects and ability to continue operations. </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to risks common to companies in the biopharmaceutical industry. There can be no assurance that the Company’s research and development will be successfully completed, that adequate protection for its intellectual property will be maintained, that any products developed will obtain required regulatory approval, or that any approved products will be commercially viable. Even if the development efforts are successful, it is uncertain when, if ever, the Company will generate significant product sales and ultimately net income. </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:3.4%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Coronavirus Pandemic </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2020, the World Health Organization declared the COVID-19 outbreak a pandemic. The worldwide COVID-19 pandemic has affected and may affect in the future the Company’s ability to initiate and complete preclinical studies, delay the initiation and completion of its current and planned clinical trials, disrupt regulatory activities or have other adverse effects on its business, results of operations, financial condition and prospects. In addition, the pandemic has caused substantial disruption in the financial markets and may adversely impact economies worldwide, both of which could adversely affect the Company’s business, operations and ability to raise funds to support its operations. </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company cannot be certain what the overall impact of the COVID-19 pandemic will be on its business, and it has the potential to adversely affect its business, financial condition, results of operations and prospects. </p>
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-9300000
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	8000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-22700000
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9000000.0
CY2021Q1	us-gaap	Use Of Estimates UseOfEstimates	<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:3.4%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with U.S. GAAP requires management to make judgments, assumptions, and estimates that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of financial statements, and the reported amounts of income and expense during the reporting period. The most significant estimates relate to the determination of fair value of the Company’s common stock, determination of the fair value of stock option grants and estimates related to the amount of accrued research and development expenses as of the balance sheet date. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and makes adjustments when the facts and circumstances dictate. These estimates are based on information available as of the date of the financial statements; therefore, actual results could differ from those estimates. </p>
CY2020	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2021Q1	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2021Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:3.4%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentration of Credit Risk </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash and cash equivalents. The Company’s investment policy includes guidelines regarding the quality of the financial institutions and financial instruments and defines allowable investments that it believes minimizes the exposure to concentration of credit risk. The Company may invest in money market funds (minimum of $1 billion in assets), U.S. Treasury securities, corporate debt, bank debt, U.S. government-related agency securities, other sovereign debt, municipal debt and commercial paper. These deposits may exceed federally insured limits. The Company has not experienced any losses historically in these accounts and believes that it is not exposed to significant credit risk as our deposits are held at financial institutions that management believes to be of high credit quality. </p>
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	21000
CY2021Q1	tals	Number Of Shares Equal To Fair Value Of Contingent Equity Consideration NumberOfSharesEqualToFairValueOfContingentEquityConsideration	65186
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	131899000
CY2021Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	130212000
CY2019Q4	us-gaap	Contingent Consideration Classified As Equity Fair Value Disclosure ContingentConsiderationClassifiedAsEquityFairValueDisclosure	63000
CY2020	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	310000
CY2020Q4	us-gaap	Contingent Consideration Classified As Equity Fair Value Disclosure ContingentConsiderationClassifiedAsEquityFairValueDisclosure	373000
CY2021Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	360000
CY2021Q1	us-gaap	Contingent Consideration Classified As Equity Fair Value Disclosure ContingentConsiderationClassifiedAsEquityFairValueDisclosure	733000
CY2021Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	130203000
CY2021Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	17000
CY2021Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	8000
CY2021Q1	us-gaap	Deferred Offering Costs DeferredOfferingCosts	1289000
CY2021Q1	tals	Contract Research Organization Prepaid ContractResearchOrganizationPrepaid	556000
CY2020Q4	tals	Contract Research Organization Prepaid ContractResearchOrganizationPrepaid	558000
CY2021Q1	us-gaap	Income Tax Receivable IncomeTaxReceivable	294000
CY2021Q1	us-gaap	Interest Receivable Current InterestReceivableCurrent	183000
CY2020Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	374000
CY2021Q1	tals	Prepaid Subscriptions PrepaidSubscriptions	136000
CY2020Q4	tals	Prepaid Subscriptions PrepaidSubscriptions	70000
CY2021Q1	tals	Prepaid Service And Maintenance Contracts PrepaidServiceAndMaintenanceContracts	111000
CY2020Q4	tals	Prepaid Service And Maintenance Contracts PrepaidServiceAndMaintenanceContracts	88000
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2243000
CY2021Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2378000
CY2021Q1	us-gaap	Prepaid Insurance PrepaidInsurance	66000
CY2020Q4	us-gaap	Prepaid Insurance PrepaidInsurance	97000
CY2021Q1	us-gaap	Other Assets Current OtherAssetsCurrent	67000
CY2020Q4	us-gaap	Other Assets Current OtherAssetsCurrent	76000
CY2021Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2702000
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1263000
CY2021Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4461000
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4256000
CY2021Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2083000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2013000
CY2021Q1	us-gaap	Depreciation Depreciation	100000
CY2020	us-gaap	Depreciation Depreciation	400000
CY2021Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1377000
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	314000
CY2021Q1	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	538000
CY2021Q1	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	496000
CY2020Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	1159000
CY2021Q1	tals	Contract Research Organization Accruals Current ContractResearchOrganizationAccrualsCurrent	439000
CY2020Q4	tals	Contract Research Organization Accruals Current ContractResearchOrganizationAccrualsCurrent	521000
CY2021Q1	tals	Paid Time Off Accrual Current PaidTimeOffAccrualCurrent	177000
CY2020Q4	tals	Paid Time Off Accrual Current PaidTimeOffAccrualCurrent	139000
CY2021Q1	tals	Franchise Taxes Payable Current FranchiseTaxesPayableCurrent	48000
CY2020Q4	tals	Franchise Taxes Payable Current FranchiseTaxesPayableCurrent	156000
CY2021Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	233000
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	348000
CY2021Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2812000
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2637000
CY2021Q1	tals	Number Of Active Lease Agreements NumberOfActiveLeaseAgreements	3
CY2021Q1	us-gaap	Lessee Operating Lease Option To Extend LesseeOperatingLeaseOptionToExtend	three additional years
CY2021Q1	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	375000
CY2021Q1	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	414000
CY2021Q1	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	1285000
CY2021Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	100000
CY2020Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	100000
CY2021Q1	tals	Annual Maintenance Fee Pursuant To License Agreement AnnualMaintenanceFeePursuantToLicenseAgreement	100000
CY2020Q1	tals	Annual Maintenance Fee Pursuant To License Agreement AnnualMaintenanceFeePursuantToLicenseAgreement	100000
CY2021Q1	tals	Product Interest Rights Held Description ProductInterestRightsHeldDescription	After the first commercial sale of product, the product interest right entitles the holders to a product interest payment for each product interest right held equal to 1/48,000,000 multiplied by 9% of net product sales on a territory-by-territory basis. If the Company enters into a license of rights to develop and/or commercialize a product, the holder is entitled to a product interest payment for each product interest right equal to 1/48,000,000 multiplied by 30% of licensing income.
CY2021Q1	tals	Remaining Product Interest Rights Outstanding RemainingProductInterestRightsOutstanding	0
CY2021Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	1.07
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3456153
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.75
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	22381000
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	504229
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2745185
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.20
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	4183000
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	737319
CY2021Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	6.70
CY2021Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	24442
CY2021Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.14
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	1909
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	3.02
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	1322333
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	1.74
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	4.73
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.07
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	166000
CY2021Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	10700000
CY2021Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y6M
CY2021Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	835000
CY2020Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	123000
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-9299000
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-4848000
CY2021Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.30
CY2020Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.76
CY2021Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	7160631
CY2020Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	6390771
CY2021Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	28753377
CY2020Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12937751

Files In Submission

Name	View Source	Status
0001564590-21-032784-index-headers.html	Edgar Link	pending
0001564590-21-032784-index.html	Edgar Link	pending
0001564590-21-032784.txt	Edgar Link	pending
0001564590-21-032784-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tals-10q_20210331.htm	Edgar Link	pending
tals-10q_20210331_htm.xml	Edgar Link	completed
tals-20210331.xsd	Edgar Link	pending
tals-20210331_cal.xml	Edgar Link	unprocessable
tals-20210331_def.xml	Edgar Link	unprocessable
tals-20210331_lab.xml	Edgar Link	unprocessable
tals-20210331_pre.xml	Edgar Link	unprocessable
tals-ex311_9.htm	Edgar Link	pending
tals-ex312_8.htm	Edgar Link	pending
tals-ex321_6.htm	Edgar Link	pending
tals-ex322_7.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TRML
Tourmaline Bio, Inc. Stock $trml

2021 Q1 Form 10-Q Financial Statement

#000156459021032784 Filed on June 14, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TRML Tourmaline Bio, Inc. Stock $trml

2021 Q1 Form 10-Q Financial Statement

#000156459021032784 Filed on June 14, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TRML
Tourmaline Bio, Inc. Stock $trml